{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T04:27:51Z","timestamp":1794716871834,"version":"4.9.1"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,5,10]],"date-time":"2019-05-10T00:00:00Z","timestamp":1557446400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Chinese Academy of Medical Sciences (CAMS) Initiative for Innovative Medicine","award":["No. 2017-I2M-1-001 and 2016-I2M-1-002"],"award-info":[{"award-number":["No. 2017-I2M-1-001 and 2016-I2M-1-002"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diagn Pathol"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s13000-019-0817-1","type":"journal-article","created":{"date-parts":[[2019,5,10]],"date-time":"2019-05-10T14:44:51Z","timestamp":1557499491000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":58,"title":["Mutation profiles of follicular thyroid tumors by targeted sequencing"],"prefix":"10.1186","volume":"14","author":[{"given":"Huanli","family":"Duan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoding","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyu","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huanwen","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiyong","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,5,10]]},"reference":[{"key":"817_CR1","doi-asserted-by":"publisher","first-page":"2783","DOI":"10.1016\/s0140-6736(16)30172-6","volume":"388","author":"ME Cabanillas","year":"2016","unstructured":"Cabanillas ME, McFadden DG, Durante C. Thyroid cancer. Lancet. 2016;388:2783\u201395. \n                    https:\/\/doi.org\/10.1016\/s0140-6736(16)30172-6\n                    \n                  .","journal-title":"Lancet"},{"key":"817_CR2","unstructured":"Lloyd RV OR KG, Rosai J. 2017 WHO classification of Tumours of endocrine organs WHO\/IARC classification of Tumours,. 2017; ,4th edition, volume 10."},{"key":"817_CR3","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1089\/thy.2015.0297","volume":"25","author":"NA Cipriani","year":"2015","unstructured":"Cipriani NA, Nagar S, Kaplan SP, et al. Follicular thyroid carcinoma: how have histologic diagnoses changed in the last half-century and what are the prognostic implications? Thyroid. 2015;25:1209\u201316. \n                    https:\/\/doi.org\/10.1089\/thy.2015.0297\n                    \n                  .","journal-title":"Thyroid"},{"key":"817_CR4","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1677\/Erc-06-0023","volume":"14","author":"T Foukakis","year":"2007","unstructured":"Foukakis T, Gusnanto A, Au AYM, et al. A PCR-based expression signature of malignancy in follicular thyroid tumors. Endocr Relat Cancer. 2007;14:381\u201391. \n                    https:\/\/doi.org\/10.1677\/Erc-06-0023\n                    \n                  .","journal-title":"Endocr Relat Cancer"},{"key":"817_CR5","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1126\/science.1230062","volume":"339","author":"S Horn","year":"2013","unstructured":"Horn S, Figl A, Rachakonda PS, et al. TERT promoter mutations in familial and sporadic melanoma. Science. 2013;339:959\u201361. \n                    https:\/\/doi.org\/10.1126\/science.1230062\n                    \n                  .","journal-title":"Science"},{"key":"817_CR6","doi-asserted-by":"publisher","first-page":"2965","DOI":"10.1002\/cncr.28800","volume":"120","author":"N Wang","year":"2014","unstructured":"Wang N, Liu T, Sofiadis A, et al. TERT promoter mutation as an early genetic event activating telomerase in follicular thyroid adenoma (FTA) and atypical FTA. Cancer. 2014;120:2965\u201379. \n                    https:\/\/doi.org\/10.1002\/cncr.28800\n                    \n                  .","journal-title":"Cancer"},{"key":"817_CR7","doi-asserted-by":"publisher","first-page":"E754","DOI":"10.1210\/jc.2013-3734","volume":"99","author":"M Melo","year":"2014","unstructured":"Melo M, da Rocha AG, Vinagre J, et al. TERT promoter mutations are a major Indicator of poor outcome in differentiated thyroid carcinomas. J Clin Endocr Metab. 2014;99:E754\u201365. \n                    https:\/\/doi.org\/10.1210\/jc.2013-3734\n                    \n                  .","journal-title":"J Clin Endocr Metab"},{"key":"817_CR8","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/j.mce.2014.10.019","volume":"399","author":"M Muzza","year":"2015","unstructured":"Muzza M, Colombo C, Rossi S, et al. Telomerase in differentiated thyroid cancer: promoter mutations, expression and localization. Mol Cell Endocrinol. 2015;399:288\u201395. \n                    https:\/\/doi.org\/10.1016\/j.mce.2014.10.019\n                    \n                  .","journal-title":"Mol Cell Endocrinol"},{"key":"817_CR9","doi-asserted-by":"crossref","unstructured":"Vinagre J, Almeida A, Populo H, et al. Frequency of TERT promoter mutations in human cancers. Nat Commun. 2013; 4. Artn 2185 10.1038\/Ncomms3185.","DOI":"10.1038\/ncomms3185"},{"key":"817_CR10","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1530\/Erc-14-0359","volume":"21","author":"RY Liu","year":"2014","unstructured":"Liu RY, Xing MH. Diagnostic and prognostic TERT promoter mutations in thyroid fine-needle aspiration biopsy. Endocr Relat Cancer. 2014;21:825\u201330. \n                    https:\/\/doi.org\/10.1530\/Erc-14-0359\n                    \n                  .","journal-title":"Endocr Relat Cancer"},{"issue":"7","key":"817_CR11","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1530\/ERC-18-0050","volume":"25","author":"Johan O Paulsson","year":"2018","unstructured":"Paulsson JO, Mu N, Shabo I, et al. TERT aberrancies: a screening tool for malignancy in follicular thyroid tumours. Endocr Relat Cancer. 2018. \n                    https:\/\/doi.org\/10.1530\/ERC-18-0050\n                    \n                  .","journal-title":"Endocrine-Related Cancer"},{"key":"817_CR12","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1007\/s00428-017-2236-6","volume":"471","author":"A Proietti","year":"2017","unstructured":"Proietti A, Sartori C, Macerola E, et al. Low frequency of TERT promoter mutations in a series of well-differentiated follicular-patterned thyroid neoplasms. Virchows Arch. 2017;471:769\u201373. \n                    https:\/\/doi.org\/10.1007\/s00428-017-2236-6\n                    \n                  .","journal-title":"Virchows Arch"},{"key":"817_CR13","doi-asserted-by":"publisher","first-page":"R143","DOI":"10.1530\/ERC-15-0533","volume":"23","author":"R Liu","year":"2016","unstructured":"Liu R, Xing M. TERT promoter mutations in thyroid cancer. Endocr Relat Cancer. 2016;23:R143\u201355. \n                    https:\/\/doi.org\/10.1530\/ERC-15-0533\n                    \n                  .","journal-title":"Endocr Relat Cancer"},{"key":"817_CR14","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1172\/Jci85271","volume":"126","author":"I Lancia","year":"2016","unstructured":"Lancia I, Ibrahimpasic T, Boucai L, et al. Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers. J Clin Invest. 2016;126:1052\u201366. \n                    https:\/\/doi.org\/10.1172\/Jci85271\n                    \n                  .","journal-title":"J Clin Invest"},{"issue":"3","key":"817_CR15","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1007\/s40618-018-0919-8","volume":"42","author":"J. Sim\u00f5es-Pereira","year":"2018","unstructured":"Simoes-Pereira J, Moura MM, Marques IJ, et al. The role of EIF1AX in thyroid cancer tumourigenesis and progression. J Endocrinol Investig. 2018. \n                    https:\/\/doi.org\/10.1007\/s40618-018-0919-8\n                    \n                  .","journal-title":"Journal of Endocrinological Investigation"},{"key":"817_CR16","doi-asserted-by":"crossref","unstructured":"Patrinos GP. DPaAW. Molecular Diagnostics 2017.","DOI":"10.1016\/B978-0-12-802971-8.00001-8"},{"key":"817_CR17","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1148\/radiol.2533090471","volume":"253","author":"JY Kwak","year":"2009","unstructured":"Kwak JY, Kim EK, Chung WY, Moon HJ, Kim MJ, Choi JR. Association of BRAFV600E mutation with poor clinical prognostic factors and US features in Korean patients with papillary thyroid microcarcinoma. Radiology. 2009;253:854\u201360. \n                    https:\/\/doi.org\/10.1148\/radiol.2533090471\n                    \n                  .","journal-title":"Radiology"},{"key":"817_CR18","unstructured":"Catalogue of somatic mutations in Cancer. \n                    https:\/\/cancer.sanger.ac.uk\/cosmic\/\n                    \n                  . Accessed July 2 2018."},{"key":"817_CR19","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1038\/ng.3409","volume":"47","author":"J Tan","year":"2015","unstructured":"Tan J, Ong CK, Lim WK, et al. Genomic landscapes of breast fibroepithelial tumors. Nat Genet. 2015;47:1341\u20135. \n                    https:\/\/doi.org\/10.1038\/ng.3409\n                    \n                  .","journal-title":"Nat Genet"},{"key":"817_CR20","doi-asserted-by":"publisher","first-page":"3627","DOI":"10.1002\/cncr.29038","volume":"120","author":"YE Nikiforov","year":"2014","unstructured":"Nikiforov YE, Carty SE, Chiosea SI, et al. Highly accurate diagnosis of Cancer in thyroid nodules with follicular neoplasm\/suspicious for a follicular neoplasm cytology by ThyroSeq v2 next-generation sequencing assay. Cancer. 2014;120:3627\u201334. \n                    https:\/\/doi.org\/10.1002\/cncr.29038\n                    \n                  .","journal-title":"Cancer"},{"key":"817_CR21","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","volume":"2","author":"E Cerami","year":"2012","unstructured":"Cerami E, Gao J, Dogrusoz U, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012;2:401\u20134. \n                    https:\/\/doi.org\/10.1158\/2159-8290.CD-12-0095\n                    \n                  .","journal-title":"Cancer Discov"},{"key":"817_CR22","doi-asserted-by":"publisher","first-page":"pl1","DOI":"10.1126\/scisignal.2004088","volume":"6","author":"J Gao","year":"2013","unstructured":"Gao J, Aksoy BA, Dogrusoz U, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal. 2013;6:pl1. \n                    https:\/\/doi.org\/10.1126\/scisignal.2004088\n                    \n                  .","journal-title":"Sci Signal"},{"key":"817_CR23","unstructured":"The catalogue of somatic mutations in Cancer. \n                    https:\/\/cancer.sanger.ac.uk\/cosmic\/gene\/analysis?ln=EIF1AX#variants\n                    \n                  . Accessed 18 July 2018."},{"key":"817_CR24","unstructured":"cBioPortal for cancer genomics. \n                    http:\/\/www.cbioportal.org\/\n                    \n                  . Accessed July 4 2018."},{"key":"817_CR25","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1530\/ERC-16-0043","volume":"23","author":"A Karunamurthy","year":"2016","unstructured":"Karunamurthy A, Panebianco F, S JH, et al. Prevalence and phenotypic correlations of EIF1AX mutations in thyroid nodules. Endocr Relat Cancer. 2016;23:295\u2013301. \n                    https:\/\/doi.org\/10.1530\/ERC-16-0043\n                    \n                  .","journal-title":"Endocr Relat Cancer"},{"issue":"6","key":"817_CR26","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1089\/thy.2017.0504","volume":"28","author":"Michael C. Topf","year":"2018","unstructured":"Topf MC, Wang ZX, Tuluc M, Pribitkin EA. TERT, HRAS, and EIF1AX mutations in a patient with follicular adenoma. Thyroid. 2018. \n                    https:\/\/doi.org\/10.1089\/thy.2017.0504\n                    \n                  .","journal-title":"Thyroid"},{"key":"817_CR27","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s12022-017-9501-8","volume":"29","author":"MC Topf","year":"2018","unstructured":"Topf MC, Wang ZX, Furlong K, Miller JL, Tuluc M, Pribitkin EA. EIF1AX mutation in a patient with Hurthle cell carcinoma. Endocr Pathol. 2018;29:27\u20139. \n                    https:\/\/doi.org\/10.1007\/s12022-017-9501-8\n                    \n                  .","journal-title":"Endocr Pathol"},{"issue":"2","key":"817_CR28","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1007\/s12020-018-1611-7","volume":"62","author":"Marialuisa Sponziello","year":"2018","unstructured":"Sponziello M, Silvestri G, Verrienti A, et al. A novel nonsense EIF1AX mutation identified in a thyroid nodule histologically diagnosed as oncocytic carcinoma. Endocrine. 2018. \n                    https:\/\/doi.org\/10.1007\/s12020-018-1611-7\n                    \n                  .","journal-title":"Endocrine"},{"key":"817_CR29","doi-asserted-by":"publisher","first-page":"2318","DOI":"10.1093\/hmg\/ddu749","volume":"24","author":"JW Kunstman","year":"2015","unstructured":"Kunstman JW, Juhlin CC, Goh G, et al. Characterization of the mutational landscape of anaplastic thyroid cancer via whole-exome sequencing. Hum Mol Genet. 2015;24:2318\u201329. \n                    https:\/\/doi.org\/10.1093\/hmg\/ddu749\n                    \n                  .","journal-title":"Hum Mol Genet"},{"key":"817_CR30","doi-asserted-by":"publisher","DOI":"10.21037\/gs.2017.08.02","volume-title":"How to handle borderline\/precursor thyroid tumors in management of patients with thyroid nodules.","author":"K Kennichi","year":"2018","unstructured":"Kennichi K. How to handle borderline\/precursor thyroid tumors in management of patients with thyroid nodules.; 2018. \n                    https:\/\/doi.org\/10.21037\/gs.2017.08.02\n                    \n                  ."},{"key":"817_CR31","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.ejca.2018.12.003","volume":"108","author":"C Bournaud","year":"2019","unstructured":"Bournaud C, Descotes F, Decaussin-Petrucci M, et al. TERT promoter mutations identify a high-risk group in metastasis-free advanced thyroid carcinoma. Eur J Cancer. 2019;108:41\u20139. \n                    https:\/\/doi.org\/10.1016\/j.ejca.2018.12.003\n                    \n                  .","journal-title":"Eur J Cancer"},{"key":"817_CR32","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1530\/EJE-17-0456","volume":"177","author":"YS Song","year":"2017","unstructured":"Song YS, Lim JA, Min HS, et al. Changes in the clinicopathological characteristics and genetic alterations of follicular thyroid cancer. Eur J Endocrinol. 2017;177:465\u201373. \n                    https:\/\/doi.org\/10.1530\/EJE-17-0456\n                    \n                  .","journal-title":"Eur J Endocrinol"},{"key":"817_CR33","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1089\/thy.2015.0527","volume":"26","author":"SY Sohn","year":"2016","unstructured":"Sohn SY, Park WY, Shin HT, et al. Highly concordant key genetic alterations in primary tumors and matched distant metastases in differentiated thyroid Cancer. Thyroid. 2016;26:672\u201382. \n                    https:\/\/doi.org\/10.1089\/thy.2015.0527\n                    \n                  .","journal-title":"Thyroid"},{"key":"817_CR34","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1002\/cncy.21474","volume":"122","author":"LA Radkay","year":"2014","unstructured":"Radkay LA, Chiosea SI, Seethala RR, et al. Thyroid nodules with KRAS mutations are different from nodules with NRAS and HRAS mutations with regard to cytopathologic and histopathologic outcome characteristics. Cancer Cytopathol. 2014;122:873\u201382. \n                    https:\/\/doi.org\/10.1002\/cncy.21474\n                    \n                  .","journal-title":"Cancer Cytopathol"},{"key":"817_CR35","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1111\/j.1349-7006.2010.01769.x","volume":"102","author":"Z Liu","year":"2011","unstructured":"Liu Z, Zhou G, Nakamura M, et al. Encapsulated follicular thyroid tumor with equivocal nuclear changes, so-called well-differentiated tumor of uncertain malignant potential: a morphological, immunohistochemical, and molecular appraisal. Cancer Sci. 2011;102:288\u201394. \n                    https:\/\/doi.org\/10.1111\/j.1349-7006.2010.01769.x\n                    \n                  .","journal-title":"Cancer Sci"},{"key":"817_CR36","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s00428-009-0798-7","volume":"455","author":"V Hofman","year":"2009","unstructured":"Hofman V, Lassalle S, Bonnetaud C, et al. Thyroid tumours of uncertain malignant potential: frequency and diagnostic reproducibility. Virchows Arch. 2009;455:21\u201333. \n                    https:\/\/doi.org\/10.1007\/s00428-009-0798-7\n                    \n                  .","journal-title":"Virchows Arch"},{"key":"817_CR37","doi-asserted-by":"publisher","first-page":"R499","DOI":"10.1530\/ERC-16-0372","volume":"23","author":"V Marotta","year":"2016","unstructured":"Marotta V, Sciammarella C, Colao A, Faggiano A. Application of molecular biology of differentiated thyroid cancer for clinical prognostication. Endocr Relat Cancer. 2016;23:R499\u2013515. \n                    https:\/\/doi.org\/10.1530\/ERC-16-0372\n                    \n                  .","journal-title":"Endocr Relat Cancer"},{"key":"817_CR38","first-page":"687","volume":"13","author":"YE Nikiforov","year":"1996","unstructured":"Nikiforov YE, Nikiforova MN, Gnepp DR, Fagin JA. Prevalence of mutations of ras and p53 in benign and malignant thyroid tumors from children exposed to radiation after the Chernobyl nuclear accident. Oncogene. 1996;13:687\u201393.","journal-title":"Oncogene"},{"key":"817_CR39","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1089\/thy.2017.0318","volume":"28","author":"VD Yakushina","year":"2018","unstructured":"Yakushina VD, Lerner LV, Lavrov AV. Gene fusions in thyroid Cancer. Thyroid. 2018;28:158\u201367. \n                    https:\/\/doi.org\/10.1089\/thy.2017.0318\n                    \n                  .","journal-title":"Thyroid"},{"key":"817_CR40","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1111\/pin.12270","volume":"65","author":"K Mochizuki","year":"2015","unstructured":"Mochizuki K, Kondo T, Oishi N, et al. Low frequency of PAX8-PPARgamma rearrangement in follicular thyroid carcinomas in Japanese patients. Pathol Int. 2015;65:250\u20133. \n                    https:\/\/doi.org\/10.1111\/pin.12270\n                    \n                  .","journal-title":"Pathol Int"}],"container-title":["Diagnostic Pathology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13000-019-0817-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13000-019-0817-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13000-019-0817-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,8]],"date-time":"2020-05-08T19:13:38Z","timestamp":1588965218000},"score":1,"resource":{"primary":{"URL":"https:\/\/diagnosticpathology.biomedcentral.com\/articles\/10.1186\/s13000-019-0817-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,10]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["817"],"URL":"https:\/\/doi.org\/10.1186\/s13000-019-0817-1","relation":{},"ISSN":["1746-1596"],"issn-type":[{"value":"1746-1596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,10]]},"assertion":[{"value":"28 February 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 April 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 May 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The institutional review board of Peking Union Medical College Hospital approved the study. For this retrospective study formal informed consent is not required.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"39"}}